Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin Jul 08 | 2019Biocon Malaysian Facility Receives Additional 483 Observations From FDAPurchase Blast
$599
Posted in: Dual/triple agonist Jul 08 | 2019Janssen-Hanmi Ends Ph2 Dual Agonist; Sanofi Efpeg Deal RestructuredPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery Jul 03 | 2019Connected Care: Sanofi/Biocorp Exclusive Data PartnershipPurchase Blast
$599
Posted in: Insulin Delivery Jul 01 | 2019Beta Bionics Raises $63M in Series B2 FinancingPurchase Blast
$599
Posted in: Glucose Monitoring Jul 01 | 2019Thoughts on OneDrop/Apple BGM DistributionPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Jun 28 | 2019Livongo Files for IPOPurchase Blast
$599
Posted in: Glucagon Jun 28 | 2019Xeris/Insulet Partnership Discontinued? Ph2 Xeris Glucagon Bariatric Surgery TrialPurchase Blast
$599
Posted in: Other, SGLT2i Jun 27 | 2019HF Trial Draft Guidance Issued by FDA; Public Hearing in July 2019Purchase Blast
$599
Posted in: GLP-1RA, SGLT2i Jun 27 | 2019High-dose Trulicity Topline Results; Jardiance Fast Track Designation for HFPurchase Blast
$599
Posted in: Bolus Insulin, DPP-IVi, GLP-1RA, GLP-1RA + Basal, SGLT2i Jun 24 | 2019DECLARE CHMP Decision This Week; Sanofi BS-Aspart Filed in EU? CHMP Agenda HighlightsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other Jun 20 | 2019Adocia's Pramlintide + Insulin Combo (ADO09) Ph1b Trial Posted on CT.govPurchase Blast
$599
Posted in: GLP-1RA Jun 19 | 2019New Semaglutide High-Dose T2DM Ph3 Trial (SUSTAIN FORTE)Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other Jun 19 | 2019Sanofi R&D Re-focusing; R&D Layoffs in France and GermanyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Jun 19 | 2019New Tirzepatide vs. Ozempic H2H Ph3 Trial (SURPASS-2)Purchase Blast
$599
Posted in: Glucagon Jun 17 | 2019Xeris Glucagon Ph3 Top-line Data vs. Novo's GlucaGenPurchase Blast
$599
Posted in: Insulin Delivery Jun 13 | 2019Connected Care: Biocorp Receives CE Mark for MallyaPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
